Maybe I was asleep at the wheel, but I think this is the first time I've seen the drug BioMS is developing referred to by anything other than MBP8298. Apparently, it is called 'dirucotide' now.
Submitted by zimba (not verified) on Mon, 2008-07-14 12:28.
"According to analyst Christine Charette...the Multiple Sclerosis market is worth just shy of $7-million and is expected to grow substantially in the coming years as more effective drugs come to market. "
The cynic in me wonders why anyone would want to cure such a lucrative disease.
Submitted by Marla Eglowstein, MD (not verified) on Fri, 2008-08-01 09:18.
What an interesting viewpoint. I have often wondered about this myself. I do know that there are many dedicated people in these companies that sincerely want to find the cure, though, and these drugs have helped so many of us that I can't begrudge them totally. Let's hope that altruism continues to motivate...
"According to analyst
"According to analyst Christine Charette...the Multiple Sclerosis market is worth just shy of $7-million and is expected to grow substantially in the coming years as more effective drugs come to market. "
The cynic in me wonders why anyone would want to cure such a lucrative disease.
That has to be a typo - it's
That has to be a typo - it's easily 7bn
***
Art Mellor, Accelerated Cure Project for MS, art-msnews -at- acceleratedcure.com
I agree. That may just refer
I agree. That may just refer to Canada (where the linked website is based.)
What an interesting
What an interesting viewpoint. I have often wondered about this myself. I do know that there are many dedicated people in these companies that sincerely want to find the cure, though, and these drugs have helped so many of us that I can't begrudge them totally. Let's hope that altruism continues to motivate...
Post new comment